Abivax SA reports results for the quarter ended June 30 - Earnings Summary

• Abivax SA ABVX.OQ reported a quarterly adjusted loss of 76 cents​​ per share for the quarter ended June 30. The mean expectation of three analysts for the quarter was for a loss of 79 cents per share. Wall Street expected results to range from -81 cents to -78 cents per share.

• Revenue was €1.09 million​; analysts expected €1.19 million.

• Abivax SA's reported EPS for the quarter was a loss of 76 cents​.

• The company reported a quarterly loss of €48.41 million.

• Abivax SA shares had risen by 1,050.7% this quarter and gained 1,102.6% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 20.8% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for Abivax SA is $95.00, about 5.3% above its last closing price of $90.00

This summary was machine generated from LSEG data September 8 at 11:03 p.m. UTC. ​All figures in euros unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)